Balance Sheet
Cash Flow Statement
AcquisitionsAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

GeneDx Holdings (WGSWW) Cash from Operations (2020 - 2025)

GeneDx Holdings has reported Cash from Operations over the past 6 years, most recently at 3090000.0 for Q4 2025.

  • Quarterly results put Cash from Operations at 3090000.0 for Q4 2025, up 2.92% from a year ago — trailing twelve months through Dec 2025 was 33279000.0 (up 216.78% YoY), and the annual figure for FY2025 was 33279000.0, up 216.78%.
  • Cash from Operations for Q4 2025 was 3090000.0 at GeneDx Holdings, down from 15767000.0 in the prior quarter.
  • Over the last five years, Cash from Operations for WGSWW hit a ceiling of 15767000.0 in Q3 2025 and a floor of 88362000.0 in Q3 2022.
  • Median Cash from Operations over the past 5 years was 35543000.0 (2023), compared with a mean of 34247650.0.
  • Biggest five-year swings in Cash from Operations: plummeted 19292.69% in 2021 and later skyrocketed 458.75% in 2025.
  • GeneDx Holdings' Cash from Operations stood at 51985000.0 in 2021, then dropped by 24.37% to 64654000.0 in 2022, then skyrocketed by 53.82% to 29858000.0 in 2023, then soared by 89.34% to 3183000.0 in 2024, then increased by 2.92% to 3090000.0 in 2025.
  • The last three reported values for Cash from Operations were 3090000.0 (Q4 2025), 15767000.0 (Q3 2025), and 10420000.0 (Q2 2025) per Business Quant data.